Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Karen Basu, PhD"'
Autor:
Lars-Olof Hattenbach, MD, PhD, Francis Abreu, PhD, Pablo Arrisi, PhD, Karen Basu, PhD, Carl J. Danzig, MD, Robyn Guymer, MD, PhD, Zdenka Haskova, MD, PhD, Jeffrey S. Heier, MD, Aachal Kotecha, PhD, Ying Liu, PhD, Anat Loewenstein, MD, András Seres, MD, Jeffrey R. Willis, MD, PhD, Charles C. Wykoff, MD, PhD, Liliana P. Paris, MD, PhD
Publikováno v:
Ophthalmology Science, Vol 3, Iss 3, Pp 100302- (2023)
Purpose: Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration. The phase III BA
Externí odkaz:
https://doaj.org/article/868cf61b8f6b4378aa110bd7320825d8
Autor:
Nicole Eter, MD, PhD, Rishi P. Singh, MD, Francis Abreu, PhD, Kemal Asik, PhD, Karen Basu, PhD, Caroline Baumal, MD, Andrew Chang, PhD, Karl G. Csaky, MD, Zdenka Haskova, MD, PhD, Hugh Lin, MD, Carlos Quezada Ruiz, MD, Paisan Ruamviboonsuk, MD, David Silverman, MSc, MRCOphth, Charles C. Wykoff, MD, PhD, Jeffrey R. Willis, MD, PhD
Publikováno v:
Ophthalmology Science, Vol 2, Iss 1, Pp 100111- (2022)
Purpose: Faricimab is a novel anti–angiopoietin-2 and anti–vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities for both VEGF and angiopoietin-2. It is postulated that targeting angiogenic factors a
Externí odkaz:
https://doaj.org/article/709fe9164f104f6b90d25b01ec8888bb
Autor:
Arshad M. Khanani, MD, MA, Robyn H. Guymer, MD, PhD, Karen Basu, PhD, Heather Boston, MSc, Jeffrey S. Heier, MD, Jean-François Korobelnik, MD, Aachal Kotecha, PhD, Hugh Lin, MD, MBA, David Silverman, MBChB, MRCOphth, Balakumar Swaminathan, MSc, Jeffrey R. Willis, MD, PhD, Young Hee Yoon, MD, PhD, Carlos Quezada-Ruiz, MD
Publikováno v:
Ophthalmology Science, Vol 1, Iss 4, Pp 100076- (2021)
Purpose: To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) trials that aimed to assess efficacy, safety, and durability of faricimab, the f
Externí odkaz:
https://doaj.org/article/4e1a35a48b634c0c9a19648d30c76ede